Promente Sp. z o.o.

The Centrum Neurologii i Psychogeriatrii w Bydgoszczy at Promente Sp. z o.o. is dedicated to advancing therapies for neurodegenerative conditions, with a primary focus on Alzheimer’s Disease and its early stages. Current studies aim to evaluate the safety and potential of innovative antibodies to slow disease progression and preserve cognitive function.

• Alzheimer’s Disease – testing disease‑modifying agents to reduce cognitive decline.
• Early Alzheimer’s Disease – assessing safety and efficacy of novel monoclonal antibodies.
• Prodromal or mild Alzheimer’s – measuring impact on functional and global outcomes.

Findings from these trials could provide new options for patients and inform future standards of care in dementia treatment.

Research at the site also targets major mood disorders, especially Major Depressive Disorder and forms that are resistant to standard therapy. Studies explore new pharmacologic mechanisms, such as kappa opioid receptor antagonism and adjunctive agents, to improve symptom relief and sustain remission.

• Treatment‑resistant depression – evaluating novel compounds as add‑on therapy.
• Depression with insomnia symptoms – testing agents that address both mood and sleep.
• Long‑term safety of emerging antidepressants – monitoring tolerability over extended periods.

The goal is to broaden effective treatment choices for patients who have not responded to existing antidepressants, ultimately enhancing quality of life.